{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2000"],"condition":["Colorectal Cancer","Colorectal Neoplasms","Cancer"],"disease":["Colorectal Cancer","Colorectal Neoplasms","Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2012683"],"study_start_month":["8"],"keyword":["Metastatic Colorectal Cancer","Bevacizumab"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"A Study to Evaluate Avastin in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer","description":"This Phase II, multicenter, double-blind, randomized, active-controlled trial is designed to evaluate the efficacy and safety of rhuMAb VEGF (Avastin) when administered at a dose of 5 mg/kg every 2 weeks in combination with 5 FU (fluorouracil)/leucovorin versus 5 FU/leucovorin alone in subjects with previously untreated metastatic colorectal cancer who are not optimal candidates to receive first-line CPT-11 (irinotecan). A total of 48 doses of rhuMAb VEGF may be administered during this study (maximum of 96 weeks of therapy).","dates":{"creation":"2000-08-15"},"accession":"2012683","cross_references":{"ClinicalTrials___gov":["NCT00109226"]}}